EarningsQ2 2026 Earnings Report
MX:VTRS Q2 2026 EPS Results
Actual EPS$12.49
Consensus EPS$10.88
Beat/MissBeat by +$1.61
One Year Ago EPS$11.22
MX:VTRS Q2 2026 Revenue Results
Actual Revenue$68.08B
Expected Revenue$66.51B
Beat/MissBeat by +$1.57B
YoY Revenue Growth+5.05%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeBefore Open
Conference CallThursday, August 6, 2026
MX:VTRS Upcoming Earnings
Viatris's next earnings date is estimated for November 9, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:VTRS Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed predominantly positive operational and strategic momentum: the company beat expectations in Q2 on revenue, EBITDA and EPS, raised full-year guidance across key metrics, showed margin improvement, strong cash generation, aggressive capital returns, meaningful pipeline and regulatory progress (Gwyn Lo approval, Nefecon topline, Phase III programs on track). Offsetting this, notable near-term challenges include Nashik manufacturing disruptions (with a $100–$150 million H2 revenue headwind), emerging markets supply constraints, competitive pressure in some developed-market products, and China procurement policy uncertainty that may moderate future growth. Overall, management framed the challenges as mostly short-term and fully considered in the updated guidance while emphasizing long-term growth opportunities and financial flexibility.Company Guidance
Total Revenue and Operational Growth
Q2 2026 total revenues of $3.8 billion, representing ~3.5% operational year-over-year revenue growth, driven by strength across multiple geographies and product categories.
Profitability Metrics Beat Expectations
Adjusted EBITDA of $1.2 billion and adjusted EPS of $0.69 in Q2 2026, results that exceeded company expectations and supported management's decision to raise full-year guidance.
Gross Margin and Cost Discipline
Adjusted gross margin improved to 57.5% for the quarter, nearly a 1 percentage-point improvement year-over-year; operating expenses declined as a percent of revenue reflecting realization of strategic review savings and SG&A discipline.
Strong China Performance and Digital Channel Growth
Greater China net sales increased 16% year-over-year, driven by cardiovascular portfolio and established brands; e-commerce channel sales in China grew ~36% year-over-year and represent ~10–15% of the China business.
Developed Markets and Complex Generics Momentum
Developed markets net sales rose ~2% year-over-year with North America up ~1%, driven by complex generics, transdermal products and complex injectable portfolio (including octreotide and iron sucrose); company is on track for >100 new product approvals in 2026 with 70 approvals in H1.
Pipeline and Regulatory Milestones
FDA approval received for Gwyn Lo (once-weekly transdermal contraceptive) with launch expected later in 2026; positive Phase III topline for Nefecon in Japan with a targeted NDA submission by end of 2026; pitolisant and other key filings in final review stages; Phase III programs for selatogrel and cenerimod remain on track with important readouts expected in H1 2027.
Capital Allocation and Balance Sheet Actions
Deployed approximately $1.4 billion of capital year-to-date, returned ~$550 million to shareholders (dividends and repurchases), repurchased ~$270 million of shares, repaid ~$900 million of matured debt and ended the quarter with gross leverage of ~2.9x (below the midpoint of 2.8–3.2x target range).
Free Cash Flow and Liquidity
Generated $329 million of free cash flow in the quarter (or $449 million excluding transaction and restructuring-related items); expects approximately $1.6 billion of deployable capital for the remainder of 2026, including ~$380 million pretax from Biocon stake monetization.
Guidance Raised Across Key Metrics
Raised 2026 guidance midpoints: implies ~2% operational revenue growth, ~5% adjusted EBITDA growth and ~7% adjusted EPS growth versus prior year, reflecting confidence in execution despite known headwinds.
MX:VTRS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed